Login to Your Account

Rigontec GmbH, a spinout from the University of Bonn in Germany, took in €9.45 million (US$12 million) in a first closing of a series A round to take forward an RNA-based approach to immunotherapy, based on activating retinoic acid inducible protein I (RIG-I), a pathogen-associated molecular pattern that recognizes certain forms of viral RNA.
One of the academic lynchpins of UK biotech, John Martin, has attracted £15.5 million (US$24.9 million) in private equity for Magnus Life Sciences Ltd., a start-up shaped to overcome his frustrations at current shortcomings and gaps in the process of translating research from lab to bedside.
Established a dozen years ago, Domainex Ltd. is familiar to drug developers – especially in the UK, where the company spun out of University College London – as a contract research organization.
More Newco News Headlines

Cast Your Vote

Has biotech’s bubble burst?: